表紙
市場調查報告書

關注市場分析:皮膚T細胞淋巴瘤 (CTCL)

Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

出版商 Datamonitor Healthcare 商品編碼 603905
出版日期 內容資訊 英文 48 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:皮膚T細胞淋巴瘤 (CTCL) Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)
出版日期: 2019年12月04日內容資訊: 英文 48 Pages
簡介

全球皮膚T細胞淋巴瘤 (CTCL)的發病數預計從2016年的約13,600件,至2025年增加到16,100件。

本報告提供全球皮膚T細胞淋巴瘤 (CTCL)的治療藥的市場調查,疾病的背景、概要,發病數的十年預測,主要的治療方法,已上市藥物及藥物開發平台趨勢,授權、資產收購等企業間的主要交易趨勢,專利資訊,臨床試驗狀況等彙整資料。

要點

疾病的背景

  • 亞型

治療

  • 局部療法 (Skin-directed therapy:SDT)
  • 全身療法 (Systemic therapy:ST)

流行病學

已上市藥物

  • 核准:各國

開發平台藥物

今後主要的活動

授權、資產收購等的交易

本源專利

商機

臨床試驗環境

  • 贊助商:各進展狀況
  • 贊助商:各階段
  • 近幾年的活動

文獻

  • 處方資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0183413

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, key regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 15,200 incident cases of cutaneous T-cell lymphoma (CTCL) worldwide, and forecasts that number to increase to 18,060 incident cases by

2026. In 2017, there were approximately 5,930 incident cases of CTCL in the US and five major EU markets (France, Germany, Italy, Spain and the UK), which is forecast to increase to 6,160 incident cases by

2026. Datamonitor Healthcare estimates that there were approximately 41,900 10-year prevalent cases of CTCL in the US and five major EU markets in 2017, which is expected to increase to 45,030 cases by

2026. Approved drugs in the CTCL space target antibody-drug conjugate, cluster of differentiation 30, tumor necrosis factor receptor superfamily member 8, microtubules, histone deacetylase, interleukin-2, protein synthesis, chemokine receptor 4, retinoid X receptors, retinoid receptors, and DNA synthesis. These drugs are administered via the intravenous, topical, and oral routes.

The majority of industry-sponsored drugs in active clinical development for CTCL are in Phase II, with only one drug in Phase III. Therapies in development for CTCL focus on a wide variety of targets. The greatest proportion of pipeline drugs in development are administered intravenously, with the remainder being tested in oral, topical, intratumoral, and subcutaneous formulations.

High-impact upcoming events for drugs in the CTCL space comprise topline Phase III trial results for SGX301, and topline Phase II trial results for resminostat, AFM13, and cobomarsen.

The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.3%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 13 licensing and asset acquisition deals involving CTCL drugs during 2014-19. The $298.8m definitive agreement signed in 2019 between Spectrum Pharmaceuticals and Acrotech Biopharma for the sale of seven FDA-approved hematology/oncology products was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for CTCL have been in the early and mid-phases of development, with 88% of trials in Phase I-II, and only 12% in Phase III-IV.

The US has a substantial lead in the number of CTCL clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the CTCL space is dominated by completed trials. Celgene, Merck & Co, Ligand, and Takeda have the highest number of completed clinical trials for CTCL, with five trials each.

Celgene leads the industry sponsors with the highest overall number of clinical trials for CTCL, followed by Merck & Co

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Subtypes

10 TREATMENT

10 Skin-directed therapy

10 Systemic therapy

12 EPIDEMIOLOGY

14 Incidence methodology for the US and five major EU markets

16 Prevalence methodology for the US and five major EU markets

19 MARKETED DRUGS

22 PIPELINE DRUGS

29 RECENT EVENTS AND ANALYST OPINION

29 Copiktra for CTCL (July 25, 2019)

29 Copiktra for CTCL (March 6, 2019)

30 Multiple Drugs for CTCL (January 17, 2019)

31 Copiktra for CTCL (December 3, 2018)

34 KEY UPCOMING EVENTS

35 KEY REGULATORY EVENTS

35 Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018

36 PROBABILITY OF SUCCESS

37 LICENSING AND ASSET ACQUISITION DEALS

37 Mallinckrodt, Transimmune Collaborate On Photopheresis

39 PARENT PATENTS

40 REVENUE OPPORTUNITY

41 CLINICAL TRIAL LANDSCAPE

42 Sponsors by status

43 Sponsors by phase

45 BIBLIOGRAPHY

45 Prescription information

47 APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Global trends in incident cases of CTCL, 2017-26
  • 16 Figure 2: Trends in incident cases of CTCL, US and 5EU, 2017-26
  • 22 Figure 3: Overview of pipeline drugs for CTCL in the US
  • 23 Figure 4: Pipeline drugs for CTCL, by company
  • 23 Figure 5: Pipeline drugs for CTCL, by drug type
  • 23 Figure 6: Pipeline drugs for CTCL, by classification
  • 33 Figure 7: Copiktra for CTCL (December 3, 2018): Phase I - w/Romidepsin or Bortezomib (TCLs) (MSKCC)
  • 34 Figure 8: Key upcoming events in CTCL
  • 36 Figure 9: Probability of success in the CTCL pipeline
  • 37 Figure 10: Licensing and asset acquisition deals in CTCL, 2014-19
  • 39 Figure 11: Parent patents in CTCL
  • 41 Figure 12: Clinical trials in CTCL
  • 41 Figure 13: Top 10 drugs for clinical trials in CTCL
  • 42 Figure 14: Top 10 companies for clinical trials in CTCL
  • 42 Figure 15: Trial locations in CTCL
  • 43 Figure 16: CTCL trials status
  • 44 Figure 17: CTCL trials sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Global incident cases of CTCL, 2017-26
  • 15 Table 2: Incident cases of CTCL, US and 5EU, 2017-26
  • 17 Table 3: 10-year prevalent cases of CTCL, US and 5EU, 2017-26
  • 18 Table 4: Five-year prevalent cases of CTCL, US and 5EU, 2017-26
  • 20 Table 5: Marketed drugs for CTCL
  • 25 Table 6: Pipeline drugs for CTCL in the US
  • 29 Table 7: Copiktra for CTCL (July 25, 2019)
  • 30 Table 8: Copiktra for CTCL (March 6, 2019)
  • 31 Table 9: Multiple Drugs for CTCL (January 17, 2019)
  • 32 Table 10: Copiktra for CTCL (December 3, 2018)
  • 40 Table 11: Historical global sales, by drug ($m), 2014-18
  • 40 Table 12: Forecasted global sales, by drug ($m), 2019-23